Sally Bridget Lawlor - 04 Feb 2026 Form 4 Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)

Reporting relationship: Chief Financial Officer
Issuer ticker: QNRX
Reported as of: 04 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Feb 2026, 17:24:03 UTC
Prior SEC filing: 03 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Sally Bridget Lawlor

Key filing fact

Sally Bridget Lawlor filed Form 4 for Quoin Pharmaceuticals, Ltd. (QNRX) on 06 Feb 2026.

Key facts

This page summarizes Sally Bridget Lawlor's Form 4 filing for Quoin Pharmaceuticals, Ltd. (QNRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Feb 2026, 17:24.

Change

Previous filing in this sequence was filed on 03 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002084407 Primary reporting owner

Lawlor Sally Bridget

Relationship: Chief Financial Officer
Address: C/O QUOIN PHARMACEUTICALS LTD.,, 42127 PLEASANT FOREST COURT, ASHBURN
Signature: /s/ Sally Bridget Lawlor
Signature date: 06 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

QNRX transaction Derivative

Share Option (Right to Buy)

Award

Transaction value: $0
Shares: +85,250
Change %
Price: $0.000000
Shares after: 85,250
Date: 04 Feb 2026
Ownership: Direct
Underlying class: ADS
Underlying amount: 85,250
Exercise price: $7.37
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

Footnote F2

The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.